ESR1 and breast carcinoma: A randomized, double-blind, placebo-controlled phase II trial (LORELEI) evaluated neoadjuvant letrozole plus Taselisib versus letrozole plus placebo in postmenopausal women with ER-positive, HER2-negative, early-stage breast cancer [312].